Advertisement

Breaking Away: The Role of Homeostatic Drive in Perpetuating Depression

  • J. Tory Toole
  • Mark A. RiceJr
  • Travis J. A. Craddock
  • Barry Nierenberg
  • Nancy G. Klimas
  • Mary Ann Fletcher
  • Joel Zysman
  • Mariana Morris
  • Gordon BroderickEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1781)

Abstract

We propose that the complexity of regulatory interactions modulating brain neurochemistry and behavior is such that multiple stable responses may be supported, and that some of these alternate regulatory programs may play a role in perpetuating persistent psychological dysfunction. To explore this, we constructed a model network representing major neurotransmission and behavioral mechanisms reported in literature as discrete logic circuits. Connectivity and information flow through this biobehavioral circuitry supported two distinct and stable regulatory programs. One such program perpetuated a depressive state with a characteristic neurochemical signature including low serotonin. Further analysis suggested that small irregularities in glutamate levels may render this pathology more directly accessible. Computer simulations mimicking selective serotonin reuptake inhibitor (SSRI) therapy in the presence of everyday stressors predicted recidivism rates similar to those reported clinically and highlighted the potentially significant benefit of concurrent behavioral stress management therapy.

Key words

Computational modeling Homeostatic regulation Depression SSRI Stress Neurotransmitters Glutamate Serotonin Network complexity Regulatory logic Multi-stability 

Notes

Acknowledgments

Funding was provided by US Department of Defense Congressionally Directed Medical Research Program (CDMRP) awards (http://cdmrp.army.mil/) GW093042, GW140142 (Broderick—PI) and GW120045 (Morris—PI). This research was conducted in collaboration with the high-performance computing team at the University of Miami Center for Computational Science (CCS) (http://ccs.miami.edu).

Disclaimer: The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of Defense.

References

  1. 1.
    Substance Abuse and Mental Health Services Administration (2013) Results from the 2012 National Survey on Drug Use and Health: Mental Health Findings, NSDUH Series H-47, HHS Publication No. (SMA) 13–4805. Substance Abuse and Mental Health Services Administration, Rockville, MDGoogle Scholar
  2. 2.
    American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-V. 5. American Psychiatric Association, Washington, DCCrossRefGoogle Scholar
  3. 3.
    Greenberg PE, Fournier A, Sisitsky T, Pike CT, Kessler RC (2014) The economic burden of adults with major depressive disorder in the United States (2005 and 2010). J Clin Psychiatry 76(2):155–162Google Scholar
  4. 4.
    Antonuccio DO, Danton WG, DeNelsky GY (1995) Psychotherapy versus medication for depression: challenging the conventional wisdom with data. J Psychother Pract Res 26(6):574–585Google Scholar
  5. 5.
    Sałat K, Podkowa A, Kowalczyk P, Kulig K, Dziubina A, Filipek B, Librowski T (2015) Anticonvulsant active inhibitor of GABA transporter subtype 1, tiagabine, with activity in mouse models of anxiety, pain and depression. Pharmacol Rep 67(3):465–472CrossRefPubMedGoogle Scholar
  6. 6.
    Cuijpers P, van Straten A, Andersson G, van Oppen P (2008) Psychotherapy for depression in adults: a meta-analysis of comparative outcome studies. J Consult Clin Psychol 76(6):909CrossRefPubMedGoogle Scholar
  7. 7.
    Burcusa SL, Iacono WG (2007) Risk for recurrence in depression. Clin Psychol Rev 27(8):959–985CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Wurtman RJ, Pohorecky LA, Baliga BS (1972) Adrenocortical control of the biosynthesis of epinephrine and proteins in the adrenal medulla. Pharmacol Rev 24(2):411–426PubMedPubMedCentralGoogle Scholar
  9. 9.
    Piazza PV, Rougé-Pont F, Deroche V, Maccari S, Simon H, Le Moal M (1996) Glucocorticoids have state-dependent stimulant effects on the mesencephalic dopaminergic transmission. Proc Natl Acad Sci 93(16):8716–8720CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Yuen EY, Liu W, Karatsoreos IN, Feng J, McEwen BS, Yan Z (2009) Acute stress enhances glutamatergic transmission in prefrontal cortex and facilitates working memory. Proc Natl Acad Sci 106(33):14075–14079CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Tafet GE, Toister-Achituv M, Shinitzky M (2001) Enhancement of serotonin uptake by cortisol: a possible link between stress and depression. Cogn Affect Behav Neurosci 1(1):96–104CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Janssen SA, Arntz A, Bouts S (1998) Anxiety and pain: epinephrine-induced hyperalgesia and attentional influences. Pain 76(3):309–316CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Bergstrom DA, Walters JR (1984) Dopamine attenuates the effects of GABA on single unit activity in the globus pallidus. Brain Res 310(1):23–33CrossRefGoogle Scholar
  14. 14.
    Daw ND, Kakade S, Dayan P (2002) Opponent interactions between serotonin and dopamine. Neural Netw 15(4):603–616CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Gillard ER, Dang DQ, Stanley BG (1993) Evidence that neuropeptide Y and dopamine in the perifornical hypothalamus interact antagonistically in the control of food intake. Brain Res 628(1):128–136CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    El Mansari M, Guiard BP, Chernoloz O, Ghanbari R, Katz N, Blier P (2010) Relevance of norepinephrine–dopamine interactions in the treatment of major depressive disorder. CNS Neurosci Ther 16(3):e1–e17CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Calabresi P, Picconi B, Parnetti L, Di Filippo M (2006) A convergent model for cognitive dysfunctions in Parkinson’s disease: the critical dopamine–acetylcholine synaptic balance. Lancet Neurol 5(11):974–983CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Biello SM, Golombek DA, Harrington ME (1997) Neuropeptide Y and glutamate block each other’s phase shifts in the suprachiasmatic nucleus in vitro. Neuroscience 77(4):1049–1057CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Serfozo P, Bartfai T, Vizi ES (1986) Presynaptic effects of neuropeptide Y on [3 H] noradrenaline and [3 H] acetylcholine release. Regul Pept 16(2):117–123CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Dryden S, McCarthy HD, Malabu UH, Ware M, Williams G (1993) Increased neuropeptide Y concentrations in specific hypothalamic nuclei of the rat following treatment with methysergide: evidence that NPY may mediate serotonin’s effects on food intake. Peptides 14(4):791–796CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Herman JP, Renda A, Bodie B (2003) Norepinephrine–gamma-aminobutyric acid (GABA) interaction in limbic stress circuits: effects of reboxetine on GABAergic neurons. Biol Psychiatry 53(2):166–174CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Wahlestedt CLAES, Hakanson ROLF, Vaz CA, Zukowska-Grojec ZOFIA (1990) Norepinephrine and neuropeptide Y: vasoconstrictor cooperation in vivo and in vitro. Am J Phys Regul Integr Comp Phys 258(3):R736–R742Google Scholar
  23. 23.
    Bremner JD, Krystal JH, Southwick SM, Charney DS (1996) Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 23(1):39–51CrossRefGoogle Scholar
  24. 24.
    Southwick SM, Bremner JD, Rasmusson A, Morgan CA, Arnsten A, Charney DS (1999) Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder. Biol Psychiatry 46(9):1192–1204CrossRefGoogle Scholar
  25. 25.
    Bymaster FP, Katner JS, Nelson DL, Hemrick-Luecke SK, Threlkeld PG, Heiligenstein JH, Morin SM, Gehlert DR, Perry KW (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27(5):699–711CrossRefGoogle Scholar
  26. 26.
    Zhang K, Grady CJ, Tsapakis EM, Andersen SL, Tarazi FI, Baldessarini RJ (2004) Regulation of working memory by dopamine D4 receptor in rats. Neuropsychopharmacology 29(9):1648CrossRefGoogle Scholar
  27. 27.
    Delgado PL, Moreno FA (1999) Role of norepinephrine in depression. J Clin Psychiatry 61:5–12Google Scholar
  28. 28.
    Casey DE, Gerlach J, Christensson E (1980) Behavioral aspects of GABA-dopamine interrelationships in the monkey. Brain Res Bull 5:269–273CrossRefGoogle Scholar
  29. 29.
    Moises HC, Woodward DJ (1980) Potentiation of GABA inhibitory action in cerebellum by locus coeruleus stimulation. Brain Res 182(2):327–344CrossRefGoogle Scholar
  30. 30.
    Bankson MG, Yamamoto BK (2004) Serotonin–GABA interactions modulate MDMA-induced mesolimbic dopamine release. J Neurochem 91(4):852–859CrossRefGoogle Scholar
  31. 31.
    Edden RA, Crocetti D, Zhu H, Gilbert DL, Mostofsky SH (2012) Reduced GABA concentration in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 69(7):750–753CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Russell VA, Wiggins TM (2000) Increased glutamate-stimulated norepinephrine release from prefrontal cortex slices of spontaneously hypertensive rats. Metab Brain Dis 15(4):297–304CrossRefGoogle Scholar
  33. 33.
    Mathew SJ, Coplan JD, Smith EL, Schoepp DD, Rosenblum LA, Gorman JM (2001) Glutamate—hypothalamic-pituitary-adrenal Axis interactions: implications for mood and anxiety disorders. CNS Spectr 6(07):555–564CrossRefPubMedPubMedCentralGoogle Scholar
  34. 34.
    Carlsson A, Waters N, Holm-Waters S, Tedroff J, Nilsson M, Carlsson ML (2001) Interactions between monoamines, glutamate, and GABA in schizophrenia: new evidence. Annu Rev Pharmacol Toxicol 41(1):237–260CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Aultman JM, Moghaddam B (2001) Distinct contributions of glutamate and dopamine receptors to temporal aspects of rodent working memory using a clinically relevant task. Psychopharmacology 153(3):353–364CrossRefPubMedPubMedCentralGoogle Scholar
  36. 36.
    Paul IA, Skolnick P (2003) Glutamate and depression. Ann N Y Acad Sci 1003(1):250–272CrossRefPubMedPubMedCentralGoogle Scholar
  37. 37.
    Carrey NJ, MacMaster FP, Gaudet L, Schmidt MH (2007) Striatal creatine and glutamate/glutamine in attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 17(1):11–17CrossRefPubMedPubMedCentralGoogle Scholar
  38. 38.
    Van Praag HM, Kahn RS, Asnis GM, Wetzler S, Brown SL, Bleich A, Korn ML (1987) Denosologization of biological psychiatry or the specificity of 5-HT disturbances in psychiatric disorders. J Affect Disord 13(1):1–8CrossRefPubMedPubMedCentralGoogle Scholar
  39. 39.
    Aghajanian GK, Marek GJ (1999) Serotonin–glutamate interactions: a new target for antipsychotic drugs. Neuropsychopharmacology 21:S122–S133CrossRefGoogle Scholar
  40. 40.
    MacDermot J, Higashida H, Wilson SP, Matsuzawa H, Minna J, Nirenberg M (1979) Adenylate cyclase and acetylcholine release regulated by separate serotonin receptors of somatic cell hybrids. Proc Natl Acad Sci 76(3):1135–1139CrossRefPubMedPubMedCentralGoogle Scholar
  41. 41.
    Guiard BP, El Mansari M, Merali Z, Blier P (2008) Functional interactions between dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats with monoaminergic lesions. Int J Neuropsychopharmacol 11(5):625–639CrossRefPubMedPubMedCentralGoogle Scholar
  42. 42.
    Korsgaard S, Gerlach J, Christensson E (1985) Behavioral aspects of serotonin-dopamine interaction in the monkey. Eur J Pharmacol 118(3):245–252CrossRefPubMedPubMedCentralGoogle Scholar
  43. 43.
    O’hara R, Schröder CM, Mahadevan R, Schatzberg AF, Lindley S, Fox S, Weiner M, Kraemer HC, Noda A, Lin X, Gray HL, Hallmayer JF (2007) Serotonin transporter polymorphism, memory and hippocampal volume in the elderly: association and interaction with cortisol. Mol Psychiatry 12(6):544–555CrossRefPubMedPubMedCentralGoogle Scholar
  44. 44.
    Connor KM, Davidson JR (1998) The role of serotonin in posttraumatic stress disorder: neurobiology and pharmacotherapy. CNS Spectr 3(S2):42–51CrossRefGoogle Scholar
  45. 45.
    Charney DS, Woods SW, Goodman WK, Heninger GR (1987) Serotonin function in anxiety. Psychopharmacology 92(1):14–24CrossRefPubMedPubMedCentralGoogle Scholar
  46. 46.
    Owens MJ, Nemeroff CB (1994) Role of serotonin in the pathophysiology of depression: focus on the serotonin transporter. Clin Chem 40(2):288–295PubMedPubMedCentralGoogle Scholar
  47. 47.
    Roelands B, Meeusen R (2010) Alterations in central fatigue by pharmacological manipulations of neurotransmitters in normal and high ambient temperature. Sports Med 40(3):229–246CrossRefPubMedPubMedCentralGoogle Scholar
  48. 48.
    Keely SL, Lincoln TM, Corbin JD (1978) Interaction of acetylcholine and epinephrine on heart cyclic AMP-dependent protein kinase. Am J Phys Heart Circ Phys 234(4):H432–H438Google Scholar
  49. 49.
    Dixon JS, Jen PY, Gosling JA (2000) The distribution of vesicular acetylcholine transporter in the human male genitourinary organs and its co-localization with neuropeptide Y and nitric oxide synthase. Neurourol Urodyn 19(2):185–194CrossRefGoogle Scholar
  50. 50.
    Walker SW, Strachan MWJ, Lightly ERT, Williams BC, Bird IM (1990) Acetylcholine stimulates cortisol secretion through the M3 muscarinic receptor linked to a polyphosphoinositide-specific phospholipase C in bovine adrenal fasciculata/reticularis cells. Mol Cell Endocrinol 72(3):227–238CrossRefPubMedPubMedCentralGoogle Scholar
  51. 51.
    Kalsner S, Quillan M (1988) Presynaptic interactions between acetylcholine and adrenergic antagonists on norepinephrine release. J Pharmacol Exp Ther 244(3):879–891PubMedPubMedCentralGoogle Scholar
  52. 52.
    Leboulenger F, Benyamina M, Delarue C, Netchitailo P, Saint-Pierre S, Vaudry H (1988) Neuronal and paracrine regulation of adrenal steroidogenesis: interactions between acetylcholine, serotonin and vasoactive intestinal peptide (VIP) on corticosteroid production by frog interrenal tissue. Brain Res 453(1):103–109CrossRefPubMedPubMedCentralGoogle Scholar
  53. 53.
    Czermak C, Staley JK, Kasserman S, Bois F, Young T, Henry S, Tamagnan GD, Seibyl JP, Krystal JH, Neumeister A (2008) β2 Nicotinic acetylcholine receptor availability in post-traumatic stress disorder. Int J Neuropsychopharmacol 11(3):419–424CrossRefGoogle Scholar
  54. 54.
    Botly LC, De Rosa E (2008) A cross-species investigation of acetylcholine, attention, and feature binding. Psychol Sci 19(11):1185–1193CrossRefGoogle Scholar
  55. 55.
    Daniel JM, Dohanich GP (2001) Acetylcholine mediates the estrogen-induced increase in NMDA receptor binding in CA1 of the hippocampus and the associated improvement in working memory. J Neurosci 21(17):6949–6956CrossRefGoogle Scholar
  56. 56.
    Mendoza L, Xenarios I (2006) A method for the generation of standardized qualitative dynamical systems of regulatory networks. Theor Biol Med Model 3:13CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Thomas R (1991) Regulatory networks seen as asynchronous automata: a logical description. J Theor Biol 153(1):1–23CrossRefGoogle Scholar
  58. 58.
    Craddock TJ, Fritsch P, Rice MA Jr, del Rosario RM, Miller DB, Fletcher MA, Klimas NG, Broderick G (2014) A role for homeostatic drive in the perpetuation of complex chronic illness: gulf war illness and chronic fatigue syndrome. PLoS One 9(1):e84839CrossRefPubMedPubMedCentralGoogle Scholar
  59. 59.
    Fritsch P, Craddock TJ, del Rosario RM, Rice MA, Smylie A, Folcik VA, de Vries G, Fletcher MA, Klimas NG, Broderick G (2013) Succumbing to the laws of attraction: exploring the sometimes pathogenic versatility of discrete immune logic. Sys Biomed 1(3):179–194CrossRefGoogle Scholar
  60. 60.
    Whitley D, Garrett D, Watson JP (2003, January) Quad search and hybrid genetic algorithms. In: Genetic and evolutionary computation—GECCO 2003. Springer, Berlin, pp 1469–1480CrossRefGoogle Scholar
  61. 61.
    Müller N, Schwarz MJ (2007) The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression. Mol Psychiatry 12:988–1000CrossRefPubMedPubMedCentralGoogle Scholar
  62. 62.
    Niciu MJ, Henter ID, Luckenbaugh DA, Zarate CA Jr, Charney DS (2014) Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds. Annu Rev Pharmacol Toxicol 54:119–139CrossRefPubMedPubMedCentralGoogle Scholar
  63. 63.
    Morgan CA, Rasmusson AM, Wang S, Hoyt G, Hauger RL, Hazlett G (2002) Neuropeptide-Y, cortisol, and subjective distress in humans exposed to acute stress: replication and extension of previous report. Biol Psychiatry 52(2):136–142CrossRefPubMedGoogle Scholar
  64. 64.
    Thorsell A (2010) Brain neuropeptide Y and corticotropin-releasing hormone in mediating stress and anxiety. Exp Biol Med 235(10):1163–1167CrossRefGoogle Scholar
  65. 65.
    Schubert KO, Clark SR, Van LK et al (2017) Depressive symptom trajectories in late adolescence and early adulthood: A systematic review. Aust N Z J Psychiatry 51(5):477–499CrossRefPubMedGoogle Scholar
  66. 66.
    Anderson IM (1998) SSRIs versus tricyclic antidepressants in depressed inpatients: a meta-analysis of efficacy and tolerability. Depress Anxiety 7(S1):11–17CrossRefPubMedGoogle Scholar
  67. 67.
    Reiche EMV, Nunes SOV, Morimoto HK (2004) Stress, depression, the immune system, and cancer. Lancet Oncol 5(10):617–625CrossRefPubMedGoogle Scholar
  68. 68.
    Yirmiya R, Rimmerman N, Reshef R (2015) Depression as a microglial disease. Trends Neurosci 38(10):637–658CrossRefPubMedGoogle Scholar
  69. 69.
    Louveau A, Smirnov I, Keyes TJ, Eccles JD, Rouhani SJ, Peske JD, Derecki NC, Castle D, Mandell JW, Lee KS, Harris TH, Kipnis J (2015) Structural and functional features of central nervous system lymphatic vessels. Nature 523(7560):337–341CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Hammen C (2005) Stress and depression. Annu Rev Clin Psychol 1:293–319CrossRefPubMedGoogle Scholar
  71. 71.
    Furlong M, Oei TP (2002) Changes to automatic thoughts and dysfunctional attitudes in group CBT for depression. Behav Cogn Psychother 30(03):351–360CrossRefGoogle Scholar
  72. 72.
    Farrer L, Christensen H, Griffiths KM, Mackinnon A (2011) Internet-based CBT for depression with and without telephone tracking in a national helpline: randomised controlled trial. PLoS One 6(11):e28099CrossRefPubMedPubMedCentralGoogle Scholar
  73. 73.
    Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S (2004) Reducing the global burden of depression. Br J Psychiatry 184(5):393–403CrossRefPubMedGoogle Scholar
  74. 74.
    March J, Silva S, Petrycki S, Curry J, Wells K, Fairbank J, Burns B, Domino M, McNulty S, Vitiello B, Severe J (2004) Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: treatment for adolescents with depression study (TADS) randomized controlled trial. JAMA 292(7):807–820CrossRefPubMedGoogle Scholar
  75. 75.
    Soeteman DI, Miller M, Kim JJ (2012) Modeling the risks and benefits of depression treatment for children and young adults. Value Health 15(5):724–729CrossRefPubMedPubMedCentralGoogle Scholar
  76. 76.
    Gruwez B, Poirier MF, Dauphin A, Olié JP, Tod M (2007) A kinetic-pharmacodynamic model for clinical trial simulation of antidepressant action: application to clomipramine–lithium interaction. Contemp Clin Trials 28(3):276–287CrossRefPubMedPubMedCentralGoogle Scholar
  77. 77.
    Peacock BN, Scheiderer DJ, Kellermann GH (2017) Biomolecular aspects of depression: a retrospective analysis. Compr Psychiatry 73:168–180CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • J. Tory Toole
    • 1
  • Mark A. RiceJr
    • 1
  • Travis J. A. Craddock
    • 1
    • 2
  • Barry Nierenberg
    • 1
  • Nancy G. Klimas
    • 2
    • 3
  • Mary Ann Fletcher
    • 2
    • 3
  • Joel Zysman
    • 5
  • Mariana Morris
    • 2
    • 3
  • Gordon Broderick
    • 1
    • 4
    • 6
    Email author
  1. 1.College of Psychology, Nova Southeastern UniversityFt. LauderdaleUSA
  2. 2.Institute for Neuro-Immune Medicine, Nova Southeastern UniversityFt. LauderdaleUSA
  3. 3.Miami Veterans Affairs Medical CenterMiamiUSA
  4. 4.Department of Biomedical EngineeringRochester Institute of TechnologyRochesterUSA
  5. 5.Center for Computational Science, University of MiamiMiamiUSA
  6. 6.Center for Clinical Systems Biology, Rochester General Hospital Research InstituteRochesterUSA

Personalised recommendations